Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019480652> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2019480652 endingPage "AB118" @default.
- W2019480652 startingPage "AB118" @default.
- W2019480652 abstract "Omalizumab, a subcutaneously administered anti-IgE monoclonal antibody, is highly effective in treating patients with SRCIU. We report the treatment of omalizumab in 62 patients. Patients were followed prospectively to evaluate the efficacy of omalizumab 150mg over a 4 year period. Two subgroups were from Toronto and Quebec City. Grading symptoms was based on seven-day urticaria activity score [UAS-7] > 30; history of oral corticosteroid use; and lack of adequate response to standard treatments. The dose interval was 1-3 months. A total of 62 patients were included in the study. Overall baseline UAS-7 was 28.1 (32.2 in the Toronto group and 24.4 in the Quebec City group). For the Toronto subgroup, mean UAS during four weeks following the last omalizumab treatment was 5.7 (change of 26.5). Fifteen patients achieved remission after the first injection, six after the second, four after the third, and two after the fourth (80%). Six patients (18%) improved, but did not achieve complete remission. One patient was completely refractory to omalizumab and three patients who initially responded became refractory. For the Quebec City subgroup, overall mean UAS-7 declined from 24.2 pre-treatment, 10.1 at one month, 5.4 at 3 months, 4.7 at six months, 2.5 at 12 months, and 2.2 at 18 months. A total of 16/28 patients in this subgroup (57%) achieved complete remission. Eleven more patients improved on omalizumab therapy but not completely. One patient was refractory to the treatment. This supports the usefulness of omalizumab 150mg in patients with corticosteroid dependant SRCIU." @default.
- W2019480652 created "2016-06-24" @default.
- W2019480652 creator A5023169506 @default.
- W2019480652 creator A5039769192 @default.
- W2019480652 creator A5050806336 @default.
- W2019480652 creator A5051776381 @default.
- W2019480652 creator A5056753880 @default.
- W2019480652 creator A5060709191 @default.
- W2019480652 creator A5063424931 @default.
- W2019480652 date "2014-02-01" @default.
- W2019480652 modified "2023-09-25" @default.
- W2019480652 title "Real-Life Experiences With Omalizumab For The Treatment Of Severe Refractory Chronic Urticaria (SRCIU)" @default.
- W2019480652 doi "https://doi.org/10.1016/j.jaci.2013.12.440" @default.
- W2019480652 hasPublicationYear "2014" @default.
- W2019480652 type Work @default.
- W2019480652 sameAs 2019480652 @default.
- W2019480652 citedByCount "0" @default.
- W2019480652 crossrefType "journal-article" @default.
- W2019480652 hasAuthorship W2019480652A5023169506 @default.
- W2019480652 hasAuthorship W2019480652A5039769192 @default.
- W2019480652 hasAuthorship W2019480652A5050806336 @default.
- W2019480652 hasAuthorship W2019480652A5051776381 @default.
- W2019480652 hasAuthorship W2019480652A5056753880 @default.
- W2019480652 hasAuthorship W2019480652A5060709191 @default.
- W2019480652 hasAuthorship W2019480652A5063424931 @default.
- W2019480652 hasBestOaLocation W20194806521 @default.
- W2019480652 hasConcept C121332964 @default.
- W2019480652 hasConcept C126322002 @default.
- W2019480652 hasConcept C141071460 @default.
- W2019480652 hasConcept C141105273 @default.
- W2019480652 hasConcept C142424586 @default.
- W2019480652 hasConcept C159654299 @default.
- W2019480652 hasConcept C187212893 @default.
- W2019480652 hasConcept C203014093 @default.
- W2019480652 hasConcept C2776804153 @default.
- W2019480652 hasConcept C2778564945 @default.
- W2019480652 hasConcept C71924100 @default.
- W2019480652 hasConcept C87355193 @default.
- W2019480652 hasConceptScore W2019480652C121332964 @default.
- W2019480652 hasConceptScore W2019480652C126322002 @default.
- W2019480652 hasConceptScore W2019480652C141071460 @default.
- W2019480652 hasConceptScore W2019480652C141105273 @default.
- W2019480652 hasConceptScore W2019480652C142424586 @default.
- W2019480652 hasConceptScore W2019480652C159654299 @default.
- W2019480652 hasConceptScore W2019480652C187212893 @default.
- W2019480652 hasConceptScore W2019480652C203014093 @default.
- W2019480652 hasConceptScore W2019480652C2776804153 @default.
- W2019480652 hasConceptScore W2019480652C2778564945 @default.
- W2019480652 hasConceptScore W2019480652C71924100 @default.
- W2019480652 hasConceptScore W2019480652C87355193 @default.
- W2019480652 hasIssue "2" @default.
- W2019480652 hasLocation W20194806521 @default.
- W2019480652 hasOpenAccess W2019480652 @default.
- W2019480652 hasPrimaryLocation W20194806521 @default.
- W2019480652 hasRelatedWork W1964883444 @default.
- W2019480652 hasRelatedWork W1967215794 @default.
- W2019480652 hasRelatedWork W2024773690 @default.
- W2019480652 hasRelatedWork W2528057197 @default.
- W2019480652 hasRelatedWork W2984258781 @default.
- W2019480652 hasRelatedWork W3080305379 @default.
- W2019480652 hasRelatedWork W4212800375 @default.
- W2019480652 hasRelatedWork W4286447815 @default.
- W2019480652 hasRelatedWork W4312791617 @default.
- W2019480652 hasRelatedWork W2186272804 @default.
- W2019480652 hasVolume "133" @default.
- W2019480652 isParatext "false" @default.
- W2019480652 isRetracted "false" @default.
- W2019480652 magId "2019480652" @default.
- W2019480652 workType "article" @default.